CRYOPORT, INC. Payments to Acquire Short-term Investments
CRYOPORT, INC. (CYRX) reported Payments to Acquire Short-term Investments of $50.72 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-03-05
- CRYOPORT, INC. payments to acquire short-term investments for the quarter ending 2024-12-31 was $0.00.
- CRYOPORT, INC. payments to acquire short-term investments for the quarter ending 2024-09-30 was $799.00K.
- CRYOPORT, INC. payments to acquire short-term investments for the quarter ending 2024-06-30 was $35.88M.
- CRYOPORT, INC. payments to acquire short-term investments for the quarter ending 2024-03-31 was $14.04M.
- CRYOPORT, INC. payments to acquire short-term investments for fiscal 2024 was $50.72M, a 18.85% increase from fiscal 2023.
- CRYOPORT, INC. payments to acquire short-term investments for fiscal 2023 was $42.68M, a 73.94% decline from fiscal 2022.
- CRYOPORT, INC. payments to acquire short-term investments for fiscal 2022 was $163.79M, a 66.07% decline from fiscal 2021.
- CRYOPORT, INC. payments to acquire short-term investments for fiscal 2021 was $482.71M, a 204.09% increase from fiscal 2020.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 3 month as first filed | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 6 month as first filed | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 9 month as first filed | Payments to Acquire Short-term Investments 12 month | Payments to Acquire Short-term Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $799.00K derived: sum of 2 quarters · filed 2026-03-05 | $36.68M derived: sum of 3 quarters · filed 2026-03-05 | $50.72M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $799.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $36.68M derived: sum of 2 quarters · filed 2025-11-06 | $50.72M 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | $35.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $49.92M 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | $14.04M 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $42.68M 10-K · filed 2026-03-05 | |||||||
| 2022-12-31 | $8.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $27.18M derived: sum of 2 quarters · filed 2025-03-07 | $133.43M derived: sum of 3 quarters · filed 2025-03-07 | $163.79M 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | $18.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $125.00M derived: sum of 2 quarters · filed 2023-11-09 | $155.35M 10-Q · filed 2023-11-09 | $345.78M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-06-30 | $106.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $136.61M 10-Q · filed 2023-08-09 | $327.04M derived: sum of 3 quarters · filed 2024-03-13 | $377.32M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-03-31 | $30.35M 10-Q · filed 2023-05-04 | $220.78M derived: sum of 2 quarters · filed 2024-03-13 | $271.07M derived: sum of 3 quarters · filed 2024-03-13 | $297.74M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2021-12-31 | $190.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $240.71M derived: sum of 2 quarters · filed 2024-03-13 | $267.39M derived: sum of 3 quarters · filed 2024-03-13 | $482.71M 10-K · filed 2024-03-13 | ||||
| 2021-09-30 | $50.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $76.96M derived: sum of 2 quarters · filed 2022-11-04 | $292.28M 10-Q · filed 2022-11-04 | $314.72M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $26.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $241.99M 10-Q · filed 2022-08-04 | $264.44M derived: sum of 3 quarters · filed 2023-02-28 | $264.48M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $215.32M 10-Q · filed 2022-05-05 | $237.76M derived: sum of 2 quarters · filed 2023-02-28 | $237.80M derived: sum of 3 quarters · filed 2023-02-28 | $357.86M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $22.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $22.48M derived: sum of 2 quarters · filed 2023-02-28 | $142.54M derived: sum of 3 quarters · filed 2023-02-28 | $158.74M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $120.10M derived: sum of 2 quarters · filed 2021-11-04 | $136.29M 10-Q · filed 2021-11-04 | $136.29M 10-Q · filed 2020-11-06 | $136.44M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $120.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $136.25M 10-Q · filed 2021-08-06 | $136.25M 10-Q · filed 2020-08-10 | $136.40M derived: sum of 3 quarters · filed 2022-02-28 | $173.43M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $16.20M 10-Q · filed 2021-05-06 | $16.20M 10-Q · filed 2020-05-08 | $16.35M derived: sum of 2 quarters · filed 2022-02-28 | $53.37M derived: sum of 3 quarters · filed 2022-02-28 | $54.38M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $151.07K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $37.18M derived: sum of 2 quarters · filed 2022-02-28 | $38.19M derived: sum of 3 quarters · filed 2022-02-28 | $43.20M 10-K · filed 2022-02-28 | $43.20M 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $37.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $38.03M derived: sum of 2 quarters · filed 2020-11-06 | $43.04M 10-Q · filed 2020-11-06 | $43.05M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $6.02M 10-Q · filed 2020-08-10 | $6.03M derived: sum of 3 quarters · filed 2020-08-10 | $15.94M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $5.01M 10-Q · filed 2020-05-08 | $5.02M derived: sum of 2 quarters · filed 2020-05-08 | $14.93M derived: sum of 3 quarters · filed 2020-05-08 | $14.93M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | $8.23K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $9.92M derived: sum of 2 quarters · filed 2020-03-10 | $9.92M derived: sum of 3 quarters · filed 2020-03-10 | $9.92M 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | $9.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $9.92M derived: sum of 2 quarters · filed 2019-11-12 | $9.92M 10-Q · filed 2019-11-12 | $9.92M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | $0.00 derived: sum of 3 quarters · filed 2019-08-09 | |||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $0.00 10-K · filed 2019-03-13 | ||||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |